GSBR-1290 Phase 2a meets endpoints; significant HbA1c and weight reductions in T2DM and obesity

Structure Therapeutics Inc.

HbA1c reduction: -1.01% to -1.02% placebo-adjusted at Week 12 (p≤0.008).
Weight loss: T2DM -3.26% to -3.51% placebo-adjusted at Week 12; obesity -4.74% at Week 8 (p<0.0001).
No treatment-related SAEs; 2.8% discontinuation rate due to AEs; GI events most common.
Full 12-week obesity data expected Q2 2024; Phase 2b obesity study to start H2 2024.
Toxicology studies show >100-fold safety margin; Japanese bridging study supports global plans.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.